SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes quarterly results beat expectations and modestly raised its full-year outlook, but the stock is selling off to a new 52-week low. Traders are split between short sellers focused on weak revenue trends and competitive risks, and bulls who see the cash balance and buyback authorization as support for an undervalued business.

Basic Attention Token (BAT) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Basic Attention Token has a current supply of 1,500,000,000 with 1,495,724,656.95260575 in circulation. The last known price of Basic Attention Token is 0.13064027 USD and is up 2.94 over the last 24 hours. It is currently trading on 591 active market(s) with $15,372,551.09 traded over the last 24 hours. More information can be found at https://basicattentiontoken.org/.

Basic Attention Token

BATs sharp move higher is drawing attention as traders point to technical breakout momentum and a broader pickup in altcoins; no specific token-related catalyst is clearly confirmed. The community is largely bullish on continuation, while others warn about profit-taking and a possible pullback after the rally.

Artificial Superintelligence Alliance (FET) is a cryptocurrency launched in 2018. Artificial Superintelligence Alliance has a current supply of 2,714,384,546.672 with 2,419,135,848.3909366 in circulation. The last known price of Artificial Superintelligence Alliance is 0.16707757 USD and is up 1.84 over the last 24 hours. It is currently trading on 592 active market(s) with $193,186,396.23 traded over the last 24 hours. More information can be found at https://superintelligence.io/.

Fetch.ai

FET is drawing attention as traders discuss a possible revival in AI-focused crypto tokens and its price action, with some viewing its relative strength and project updates as reasons to accumulate. Others see it as an underperformer and warn that any rebound remains vulnerable to Bitcoin and broader crypto-market weakness.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is drawing attention ahead of the expected Q4 Phase 3 topline readout for HLP003, its investigational adjunctive treatment for major depressive disorder. Traders are split between optimism that positive data could validate the program and concern about the binary trial risk, potential dilution, and recent weak price action.

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,020,742,700.022444 with 95,020,750,177.733244 in circulation. The last known price of TRON is 0.3287714 USD and is down -6.58 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,904,975,878.16 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRON is drawing attention for a sharp decline and underperforming other altcoins that traders describe as green; bearish chart setups and talk of a corrective pullback contrast with holders viewing the weakness as a pause in its longer-term climb.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lillys Q3 earnings beat and raised sales outlook, driven by Mounjaro and Zepbound demand, are fueling the stocks breakout and bullish reaction. Skeptics point to its rich valuation and lower EPS guidance reflecting acquired R&D charges, while some question the early performance of Foundayo.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 11.42916419 USD and is up 8.20 over the last 24 hours. It is currently trading on 2313 active market(s) with $611,471,639.23 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

LINK is drawing attention for a sharp rebound and renewed buying momentum, with traders watching whether it can clear resistance and sustain a breakout. Bulls are accumulating and pointing to Chainlinks role in institutional tokenization and interoperability, while skeptics warn that the rally could fade and question whether network adoption translates into value for the token.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

Natural gas weakness tied to mild-weather forecasts and ample storage is the dominant topic, with traders noting the price slide and looking for lower entry points. Some are buying dips in anticipation of winter cold or a sharp weather-driven rebound, while others remain bearish on warm-winter risk and persistent supply.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Brazils presidential election result triggered a sharp repricing of Brazilian-linked stocks, with traders tying NUs selloff to concerns about political, fiscal, and country risk. The community is split between viewing the move as an overreaction to an unchanged business and treating the uncertainty as a reason to stay cautious.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Anticipation of Anthropics potential IPO and related S-1/prospectus developments is driving discussion, as traders view DXYZ as a proxy for the private AI company. Bulls expect the IPO and higher private valuations to lift the fund, while skeptics point to weak price reaction, uncertainty over IPO timing, and DXYZ trading below estimated NAV.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares?

T expands customer benefits with complimentary LifeMD memberships, offering virtual care, prescriptions and pharmacy services.

AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD

AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMDPR NewswireDALLAS, Sept. 15, 2026 DALLAS, Sept. 15, 2026 /PRNewswire/ -- Through an exclusive...

LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates

LifeMD (LFMD) delivered earnings and revenue surprises of +20.00% and -3.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

LifeMD's Series A Preferred Stock Crosses Above 9.5% Yield Territory

In trading on Monday, shares of LifeMD Inc's 8.875% Series A Cumulative Perpetual Preferred Stock (Symbol: LFMDP) were yielding above the 9.5% mark based on its quarterly dividend (annualized to $2.2188), with shares changing hands as low as $22.91 on the day. As of last clos...

CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Hims & Hers Expands Integrated Health Access via Platform Expansion

HIMS expands its integrated telehealth ecosystem with a new weight-loss membership and a planned Eucalyptus acquisition to broaden virtual care.

Is CAH Becoming the Backbone of US Healthcare Infrastructure?

Cardinal Health is expanding beyond drug distribution into specialty care, logistics and nuclear medicine, deepening its role in US healthcare infrastructure.

Bloomberg Businessweek Daily 5/18/2026

Today, Matt Schettenhelm, Bloomberg Intelligence Senior Litigation Analyst, breaks down a California's jury's rejection of Elon Musk's claim that Sam Altman betrayed OpenAI's original mission when it...

LifeMD (NASDAQ:LFMD) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

LifeMD (NASDAQ:LFMD - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.06). LifeMD had a negative return on equity of 83.93% and a net margin of 6.58%.The business had...

LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates

LifeMD (LFMD) delivered earnings and revenue surprises of -42.86% and +3.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The firm combines virtual medical treatment with prescription medications and over-the-counter products. It operates through the Telehealth and WorkSimpli segments. The company was founded by Justin Schreiber on May 24, 1994 and is headquartered in New York, NY.

LifeMD Inc

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Hims shares logged their best session in a month and added after-hours gains.</li><li>Novo expanded oral Wegovy access, while Citi kept a ‘Sell’ rating on Hims.</li><li>Hims continues to broaden its platform through international expansion and new services.</li></ul>Hims &amp; Hers Health Inc. shares posted their strongest session in a month on Monday and added another 0.7% in after-hours trading, with both trading days so far this year ending higher.The move came despite a cautious note from Citi, which said Novo Nordisk’s latest Wegovy announcement could pressure Hims’ GLP-1 business in 2026. Citi kept a 'Sell' rating on the stock with a $30 price target.<h2 class="st-heading-2">Novo’s Oral Wegovy Move Leaves HIMS On The Sidelines</h2>Novo Nordisk said on Monday that its oral Wegovy pill is now broadly available in the U.S., with pricing starting at $149 a month for specific doses and higher prices for larger doses later in 2026. Novo also said commercially insured patients could access the pill for as low as $25 per month.Citi said Hims was again left off Novo’s list of partners, which includes CVS Health, Costco, LifeMD and GoodRx. The firm said this likely reflects disagreements between Novo and Hims around Hims’ compounded semaglutide strategy, and added that the broader rollout of Wegovy pills could put pressure on Hims’ GLP-1 business this year.<h2 class="st-heading-2">Broader Growth Drivers Remain in Focus</h2>Hims &amp; Hers Health has spent recent months expanding its platform beyond weight loss through geographic expansion, new product launches and acquisitions. In December, the company announced the expansion of its Weight Loss Program to the UK, including the official launch of the Hers platform for eligible women, offering access to weight-management care following assessments by GMC-registered doctors. The UK offering includes branded GLP-1 options and oral non-prescription treatments.Hims has also entered Canada following the completion of its acquisition of Livewell, a Canadian digital health platform. Additionally, the company said it will acquire YourBio Health, which develops capillary whole blood sampling technology, including the TAP device that uses bladeless microneedles.&nbsp;Separately, Hims launched its Labs in-depth testing experience, which provides customers with blood-based biomarker testing and doctor-developed action plans across areas such as heart health, metabolism, hormones and inflammation. The company said it plans to expand the Labs offering over time to include additional biomarker tests, at-home testing devices and advanced diagnostics.In December, Barclays initiated coverage of Hims with an ‘Overweight’ rating and a $48 price target, noting that expectations for the business had become more reasonable and pointing to the addition of other growth drivers for FY26.<h2 class="st-heading-2">Investors Look Beyond Near-Term GLP-1 Pressure</h2>Competition in the GLP-1 weight-loss space continues to broaden. Novo Nordisk and Eli Lilly dominate the market with Wegovy and Zepbound, respectively, and Lilly’s injectable Zepbound has been shown in a head-to-head study to deliver greater average weight loss than Wegovy. Novo has since launched the first FDA-approved oral GLP-1 for weight loss, while Lilly is advancing its own oral candidate, orforglipron, which is under regulatory review. Both companies have also cut cash-pay prices for lower doses as access expands beyond insurance-covered channels.Beyond Novo and Lilly, other drugmakers are developing next-generation obesity treatments, including Lilly’s retatrutide and Novo’s CagriSema, while additional companies such as Pfizer and Structure Therapeutics are working on oral weight-loss drugs.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_55bef6044e.webp" alt="hims ss.png" width="972" height="144"><figcaption>HIMS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user said, “Injections vs pills for weight loss will be a big deal. Who wouldnt rather take a pill. HIMS needs to get Novo deal or somehow get access to sell the pill, otherwise their weight loss related revenue will tank”<stembedurl>https://stocktwits.com/Matril/message/640906333</stembedurl>Another user said that with GLP-1 pills now available through large retailers such as Costco, the downside risks are already reflected in the stock price, and added that future catalysts could include share buybacks and increased trading activity.<stembedurl>https://stocktwits.com/ros_/message/640880655</stembedurl><a href="https://stocktwits.com/symbol/HIMS">Hims’ stock</a> has risen 30% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Costco Wholesale Corp

CVS Health Corp

GoodRx Holdings Inc

Structure Therapeutics Inc - ADR

Hims & Hers Health Inc

Novo Nordisk A/S

Pfizer Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.29
Prev Close	$2.32
Open	$2.30
Dividend Yield	0.00%
50-Day Moving Average	$2.82
Beta	1.66
Avg. Volume	860,685.08
PE Ratio	-4.44

52-Week High	$5.96
52-Week Low	$2.06
Market Capitalization	$110.38M
EPS (Annual)	-$0.2263
Price to Book	13.75
Revenue Per Employee	$498,856.55

Feed

News

Sentiment

Earnings

Fundamentals

Info

LFMD Fundamentals